[
  {
    "ts": null,
    "headline": "UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $584 from $560 while maintaining a Neutral rating ahead of the company’s second-quarter earnings report. The move reflects slightly more optimistic expectations for Regeneron’s financial performance, […]",
    "url": "https://finnhub.io/api/news?id=ade4fba3ad9ebf87846deb5804b14406d1a9e5b710906c4a31787c5316826ac8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752683138,
      "headline": "UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating",
      "id": 135970758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $584 from $560 while maintaining a Neutral rating ahead of the company’s second-quarter earnings report. The move reflects slightly more optimistic expectations for Regeneron’s financial performance, […]",
      "url": "https://finnhub.io/api/news?id=ade4fba3ad9ebf87846deb5804b14406d1a9e5b710906c4a31787c5316826ac8"
    }
  }
]